GlassScriptPhysician profile
Saeed A Shah
NPI 1700831344
$48,546.09
in general payments reported to CMS, 2019-2025
15 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,456 · 2020: $1,001 · 2021: $7,933 · 2022: $781 · 2023: $745 · 2024: $16K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $6,500 · Travel and Lodging: $2,695 · Food and Beverage: $2,196 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,910.00 |
| Consulting Fee | $6,500.00 |
| Travel and Lodging | $2,694.58 |
| Food and Beverage | $2,195.89 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $37,303.78 | 2019-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $7,129.99 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $1,198.31 | 2020-2025 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $1,084.99 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $771.77 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Indivior INC. | $309.98 | 2019-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $190.99 | 2021-2024 | Uzedy, Austedo Xr |
| Abbvie INC. | $188.19 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $101.82 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.59 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $66.14 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.84 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $22.16 | 2024 | Fanapt |
| Allergan, INC. | $20.14 | 2021 | |
| Axsome Therapeutics, INC. | $18.40 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.